StreetInsider.com News Articles

Form 4 Structure Therapeutics For: Jun 17 Filed by: Russell Angus C.

Thu, 18 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260618/26667065.html

Form 4 Structure Therapeutics For: Jun 17 Filed by: Russell Angus C.

Thu, 18 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260618/26667065.html

Form 4 Structure Therapeutics For: Jun 17 Filed by: DOBMEIER ERIC

Thu, 18 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260618/26667044.html

Form 4 Structure Therapeutics For: Jun 17 Filed by: DOBMEIER ERIC

Thu, 18 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260618/26667044.html

Form 4 Structure Therapeutics For: Jun 17 Filed by: TETLOW SHARON

Thu, 18 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260618/26667045.html

Form 4 Structure Therapeutics For: Jun 17 Filed by: TETLOW SHARON

Thu, 18 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260618/26667045.html

Form 4 Structure Therapeutics For: Jun 17 Filed by: WELCH DANIEL G

Thu, 18 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260618/26667048.html

Form 4 Structure Therapeutics For: Jun 17 Filed by: WELCH DANIEL G

Thu, 18 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260618/26667048.html

Form 4 Structure Therapeutics For: Jun 17 Filed by: Waldstreicher Joanne

Thu, 18 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260618/26667052.html

Form 4 Structure Therapeutics For: Jun 17 Filed by: Waldstreicher Joanne

Thu, 18 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260618/26667052.html

Form 4 Structure Therapeutics For: Jun 17 Filed by: LOVE TED W

Thu, 18 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260618/26667059.html

Form 4 Structure Therapeutics For: Jun 17 Filed by: LOVE TED W

Thu, 18 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260618/26667059.html

Form 8-K Structure Therapeutics For: Jun 17

Thu, 18 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260618/26665944.html

Form 8-K Structure Therapeutics For: Jun 17

Thu, 18 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260618/26665944.html

Structure Therapeutics (GPCR) PT Lowered to $70 at H.C. Wainwright

Thu, 11 Jun 2026 06:42:18 -0400

(Updated - June 11, 2026 6:42 AM EDT)

H.C. Wainwright analyst Ananda Ghosh lowered the price target on Structure Therapeutics (NASDAQ: GPCR) to $70.00 (from $100.00) while maintaining a Buy rating.

The analyst commented: 'For aleniglipron, tolerability stays the key differentiator on the 2.5mg start, but absolute nausea/vomiting is class-typical, so persistence, not GI burden might be more important for commercial success. However, from landscape point of view, retatrutide's clean low-dose profile and Pfizer's once-monthly injectable creates a new bar in the same mid-BMI market the orals are chasing. For a clear win, aleniglipron must prove efficacy durability above orforglipron and elecoglipron

Structure Therapeutics (GPCR) PT Lowered to $70 at H.C. Wainwright

Thu, 11 Jun 2026 06:42:18 -0400

(Updated - June 11, 2026 6:42 AM EDT)

H.C. Wainwright analyst Ananda Ghosh lowered the price target on Structure Therapeutics (NASDAQ: GPCR) to $70.00 (from $100.00) while maintaining a Buy rating.

Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows

Tue, 09 Jun 2026 14:31:19 -0400

Investing.com -- Oral GLP-1 therapies for obesity are experiencing a fast start in the U.S. market, though utilization remains limited in the early stages of commercialization, according to a Bernstein provider survey conducted in mid-to-late May.

The survey included 25 U.S.-based healthcare providers across 14 states with various practice settings. Most respondents reported that oral GLP-1s account for 10% or less of new weekly obesity prescriptions, indicating modest current penetration.

Providers largely expect oral GLP-1s to expand the total addressable patient population rather than replace injectable therapies. The oral formulations are anticipated to attract new patient segments, particularly those who prefer to

Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows

Tue, 09 Jun 2026 14:31:19 -0400

Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows

Tue, 09 Jun 2026 14:31:19 -0400

Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows

Tue, 09 Jun 2026 14:31:19 -0400

Structure Therapeutics publishes obesity drug trial results in Nature Medicine

Fri, 05 Jun 2026 16:05:32 -0400

Structure Therapeutics Inc. (NASDAQ: GPCR) announced the publication of Phase 2b clinical trial results for its obesity treatment aleniglipron in Nature Medicine. The study, called ACCESS, evaluated the oral small molecule GLP-1 receptor agonist in people with obesity or overweight conditions with weight-related comorbidities.

The trial achieved statistical significance on primary and key secondary endpoints at 36 weeks across three maintenance dose levels. In an open-label extension study, participants continued losing weight beyond the initial 36-week period, with weight reductions of 13.3%, 16.2%, and 15.3% observed after a median 20-week follow-up in the 45 mg, 90 mg, and 120 mg dose

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

Fri, 05 Jun 2026 16:05:00 -0400

Publication presented concurrently with oral presentation at
American Diabetes Association’s 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist

Publication and presentation detail dose-dependent, clinically meaningful and
statistically significant reductions in body weight with continued weight loss beyond 36 weeks,
up to 16.2% during the open-label extension

Aleniglipron safety profile reflects well-known GI-related GLP-1 class adverse events,
with favorable tolerability profile demonstrated by an overall low (10.4%) discontinuation rate

Phase 3 program remains on track to initiate in Q3

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

Fri, 05 Jun 2026 16:05:00 -0400

Publication presented concurrently with oral presentation at
American Diabetes Association’s 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist

Publication and presentation detail dose-dependent, clinically meaningful and
statistically significant reductions in body weight with continued weight loss beyond 36 weeks,
up to 16.2% during the open-label extension

Aleniglipron safety profile reflects well-known GI-related GLP-1 class adverse events,
with favorable tolerability profile demonstrated by an overall low (10.4%) discontinuation rate

Phase 3 program remains on track to initiate in Q3

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Tue, 26 May 2026 16:05:00 -0400

SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in two upcoming healthcare conferences in June:

2026 Jefferies Global Healthcare Conference
Format: Fireside chat and 1x1 meetings
Date/time: Wednesday, June 3 at 12:15

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Tue, 26 May 2026 16:05:00 -0400

SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in two upcoming healthcare conferences in June:

2026 Jefferies Global Healthcare Conference
Format: Fireside chat and 1x1 meetings
Date/time: Wednesday, June 3 at 12:15